Effects on Memory Tasks and Daily Life Performance of a Dietary Supplement Made from Extract of Sorghum Bacopa Monnieri, Astaxanthin, Phosphatidylserine, and Vitamin E in Subjects with Amnestic Mild Cognitive Impairment

¹Rehabilitation Dept, ASL BAT, Italy

²Marsica Area, Health Care Districs of Celano, Tagliacozzo and Pescina, ASL Aquila, Italy

³Peligno-Sangrino District, Castel Sangro (AQ), Italy

⁴Santa Lucia Center, Assemini (CA), Italy

⁵Campi Salentina District, ASL Lecce, Italy

^*Corresponding author:Dr Mauro Paulmbo, Bisceglie Hospital, Viale degli Aragonesi snc – 76011, Bisceglie (BT), E-mail: [email protected]

Received Date: December 19, 2025

Published Date: February 02, 2026

Citation: Palumbo M, et al. (2026). Effects on Memory Tasks and Daily Life Performance of a Dietary Supplement Made from Extract of Bacopa Monnieri, Astaxanthin, Phosphatidylserine, and Vitamin E in Subjects with Amnestic Mild Cognitive Impairment: A Noncomparative, Exploratory, Real-Life Study. Nutraceutical Res. 5(1):17.

Copyright:: Palumbo M, et al. © (2026).

ABSTRACT

Background: Patients suffering from amnestic mild cognitive impairment are at significant risk of developing Alzheimer's disease. Since no established pharmacological treatments exist in clinical practice, emerging evidence suggests that certain supplements may help to reduce memory loss. Aim: to explore the opportunity of the neuroprotective capacity of a commercially available nutraceutical compound in a real-life setting. Methods: In this open-label, uncontrolled, observational prospective study, a combination of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E (natural mix supplement) was clinically evaluated in amnestic mild cognitive patients. A total of 100 subjects (aged 60 -79 years) underwent a battery of cognitive and daily life assessment tests. Results: At admission, patients had an impaired delayed recall test score of 11.84 ± 3.37. After 52 weeks of treatment with the dietary supplement, patients exhibited a statistically significant improvement (△_T0-T2 = +24%; p<0.001), with overall cognitive function restored to normal (MoCA test score ranging between 25-30 points). A notable improvement of about 30% was also observed in daily activity scores. Few mild adverse events were recorded. Conclusions: Due to the lack of a control/placebo group, our study cannot provide definitive evidence that the supplement can slow cognitive decline. On the other hand, our study design is appropriate for early-phase setting and to estimate a possible trend. Current findings support a plausible amelioration of disease response to a nutraceutical compound in a long-term follow-up. Further randomized and controlled studies are advisable to verify this opportunity.

Keywords: Cognitive Dysfunction, Memory Disorders, Dietary Supplementation, Nutraceuticals, Pilot Study